Ultime notizie per GRI Bio (NASDAQ:GRI) Azioni

Cohen & Steers Global Realty Majors ETF

GRI Bio

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio Inc

First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund

Grid+

GRIID Infrastructure Inc

GRINDROD SHIPPING HLDGS LTD ORD

Grin

<h3>Gainers</h3>
<ul>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock rose 50.3% to $0.64 during Friday's regular session. The market value of their outstanding shares is at $24.6 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 45.55% to $5.08. The market value of their outstanding shares is at $385.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares rose 27.44% to $1.86. The company's market cap stands at $2.5 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares rose 26.41% to $1.11. The company's market cap stands at $4.0 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 25.53% to $38.94. The market value of their outstanding shares is at $130.7 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) stock increased by 20.73% to $14.88. The market value of their outstanding shares is at $1.2 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares fell 35.1% to $1.26 during Friday's regular session. The market value of their outstanding shares is at $457.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 22.44% to $11.1. The market value of their outstanding shares is at $12.7 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 21.57% to $17.23. The company's market cap stands at $1.5 billion. </li>
<li>Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) stock fell 14.0% to $14.99. The market value of their outstanding shares is at $918.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 13.42% to $1.06. The company's market cap stands at $5.9 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 12.38% to $0.5. The market value of their outstanding shares is at $36.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

ATHA

BFRI

CDXC

ALPS ETF Trusthen & Steers Global Realty Majors ETF

LXRX

MYGN

PDEX

PLSE

TOVX

XAIR

12 Health Care Stocks Moving In Friday's Intraday Session

Including $0.8M From Recent Warrant Exercise

News

GRI Bio Raises $13.9M In Gross Proceeds Since Start Of 2024; Funds Expected To Extend Cash Runway Into Mid-Q1 2025, Supporting Interim Data From Phase 2a Study Of GRI-0621 For Idiopathic Pulmonary Fibrosis (IPF) Treatment

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 92.5% to $0.3 during Wednesday's regular session. The company's market cap stands at $9.6 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock rose 63.89% to $2.75. The market value of their outstanding shares is at $11.9 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 59.31% to $2.56. The company's market cap stands at $437.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 42.54% to $1.0. The company's market cap stands at $95.9 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 36.35% to $1.65. The company's market cap stands at $343.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 22.47% to $4.12. The market value of their outstanding shares is at $32.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares declined by 66.1% to $4.93 during Wednesday's regular session. The market value of their outstanding shares is at $132.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 27.74% to $0.33. The market value of their outstanding shares is at $4.4 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 26.44% to $0.4. The company's market cap stands at $5.4 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 25.26% to $0.72. The market value of their outstanding shares is at $2.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 25.18% to $1.07. The company's market cap stands at $2.1 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 23.73% to $1.8. The market value of their outstanding shares is at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANRO

BIVI

CNSP

CYCC

DBVT

ENSC

NUWE

SGMO

SLXN

TVGN

VRAX

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 120.0% to $0.45 during Tuesday's regular session. The company's market cap stands at $6.2 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 102.48% to $0.45. The market value of their outstanding shares is at $8.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares rose 90.15% to $2.87. The company's market cap stands at $7.4 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 41.29% to $1.29. The company's market cap stands at $268.6 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares increased by 31.15% to $3.45. The market value of their outstanding shares is at $27.5 million. </li>
<li>Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) shares increased by 28.61% to $3.67. The market value of their outstanding shares is at $160.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock fell 30.5% to $0.33 during Tuesday's regular session. The market value of their outstanding shares is at $23.9 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock fell 28.74% to $0.94. The company's market cap stands at $2.7 million. </li>
<li>Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) stock decreased by 19.52% to $6.17. The company's market cap stands at $336.1 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock decreased by 17.86% to $1.84. The market value of their outstanding shares is at $28.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares decreased by 17.15% to $5.22. The company's market cap stands at $3.4 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock declined by 16.65% to $0.65. The market value of their outstanding shares is at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNPX

HOWL

INAB

ISPC

NDRA

SNSE

VSEE

VYGR

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 150 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.38% to 42,768.98 while the NASDAQ slipped 0.43% to 18,459.79. The S&amp;P 500 also fell, dropping, 0.49% to 5,825.05.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.1% on Tuesday.
In trading on Monday, consumer discretionary shares fell by 0.9%.
Top Headline
General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) reported better-than-expected third-quarter results.
Quarterly adjusted earnings per share of $2.96 beats the street view of $2.43. Quarterly sales of $48.757 billion (+10.5%) beat the analyst consensus estimate of $44.585 billion.
The company raised 2024 adjusted EPS guidance from $9.50 – $10.50 to $10.00 – $10.50 (consensus $10.00).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares shot up 153% to $3.8400.</li>
<li>Shares of Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) got a boost, surging 144% to $0.5015</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares were also up, gaining 50% to $1.3663 after the company announced the FDA approved an accelerated pathway for ST-920 in Fabry disease. A BLA submission is expected in 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares dropped 29% to $0.9370.</li>
<li>Shares of JE Cleantech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) were down 25% to $1.67.</li>
<li>IN8bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) was down, falling 24% to $0.3598.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.34 while gold traded up 0.6% at $2,754.70.
Silver traded up 2% to $34.760 on Tuesday, while copper rose 0.8% to $4.3940.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX fell 0.1% and France's CAC 40 fell 0.2%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 fell 0.2%.
Passenger car registrations in the European Union fell by 6.1% year-over-year to 809,163 units in September following a 18.3% decline in August.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 1.39%, Hong Kong's Hang Seng Index gaining 0.1%, China's Shanghai Composite Index gaining 0.54% and India's BSE Sensex falling 1.15%.
The annual inflation rate in Hong Kong fell to 2.2% in September from 2.5% in the prior month.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41453972/top-3-defensive-stocks-that-may-keep-you-up-at-night-this-month">Top 3 Defensive Stocks That May Keep You Up At Night This Month</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

JCSE

Dow Falls Over 150 Points; General Motors Tops Q3 Views

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 134.8% to $0.48 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock rose 118.54% to $3.3. The market value of their outstanding shares is at $8.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock moved upwards by 51.51% to $0.5. The market value of their outstanding shares is at $3.7 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 43.17% to $3.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares rose 24.21% to $12.79. The market value of their outstanding shares is at $13.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares increased by 20.55% to $0.29. The market value of their outstanding shares is at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 24.7% to $0.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock declined by 21.03% to $0.62. The market value of their outstanding shares is at $15.4 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares declined by 14.11% to $0.41. The company's market cap stands at $29.5 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined by 11.32% to $312.98. The market value of their outstanding shares is at $9.7 billion. The company's, Q3 earnings came out yesterday. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares fell 9.23% to $5.02. The market value of their outstanding shares is at $210.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 8.56% to $0.64. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

APVO

HURA

MEDP

PTIX

TCBP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 134.8% to $0.48 during Tuesday's pre-market session. The company's market cap stands at $6.7 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock rose 118.54% to $3.3. The company's market cap stands at $8.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock rose 51.51% to $0.5. The market value of their outstanding shares is at $3.7 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 43.17% to $3.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 24.21% to $12.79. The company's market cap stands at $13.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares moved upwards by 20.55% to $0.29. The market value of their outstanding shares is at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 24.7% to $0.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock decreased by 21.03% to $0.62. The market value of their outstanding shares is at $15.4 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares decreased by 14.11% to $0.41. The market value of their outstanding shares is at $29.5 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares decreased by 11.32% to $312.98. The market value of their outstanding shares is at $9.7 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock fell 9.23% to $5.02. The company's market cap stands at $210.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 8.56% to $0.64. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose sharply in today's pre-market trading after the company announced that it was granted FDA clearance for its 510(k) submission related to prior design changes <a href="https://www.benzinga.com/quote/IRTC">made to the Zio AT device.</a>
iRhythm Technologies shares jumped 20.5% to $74.80 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) rose 145.7% to $3.71 in pre-market trading after jumping around 260% on Monday.</li>
<li>SRM Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) gained 82.1% to $1.34 in pre-market trading.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares surged 77.5% to $4.03 in pre-market trading after declining 55% on Monday.</li>
<li>Urgent.ly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) rose 44.5% to $0.9870 in pre-market trading.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 42.2% to $0.47 in pre-market trading after jumping around 34% on Monday.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares jumped 39.1% to $0.2864 in pre-market trading after gaining around 15% on Monday.</li>
<li>MarketWise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTW#NASDAQ">MKTW</a>) gained 24.9% to $0.7315 in pre-market trading. MarketWise's 13G filing showed BlackRock reported a 5.2% stake in the co as of Sept. 30.</li>
<li>Addex Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) climbed 21.7% to $12.95 in pre-market trading.</li>
<li>Dana Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) gained 6.9% to $11.25 in pre-market trading after declining around 6% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>IN8bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares dipped 21.3% to $0.3737 in pre-market trading after jumping around 75% on Monday.</li>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 21.2% to $1.04 in pre-market trading after announcing exercise of warrants.</li>
<li>DMC Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) fell 18% to $10.60 in pre-market trading after the company cut its third-quarter guidance and announced it is no longer actively marketing DynaEnergetics and NobelClad.</li>
<li>Sensei Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) fell 15% to $0.6633 in today's pre-market trading after jumping over 78% on Monday.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) fell 11.3% to $313.00 in pre-market trading after the company reported worse-than-expected third-quarter sales results.</li>
<li>BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares fell 10.7% to $2.35 in pre-market trading. BioVie announced the pricing of registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules.</li>
<li>Notable Labs, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTBL#NASDAQ">NTBL</a>) shares declined 9.3% to $0.3111 in pre-market trading after gaining over 10% on Monday.</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) declined 9.2% to $130.00 in pre-market trading after reporting weak quarterly earnings.</li>
<li>Knightscope, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares declined 8.9% to $12.07 in pre-market trading after surging 19% on Monday.</li>
<li>ATN International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) shares fell 8.1% to $29.30. ATN International will release third quarter results on Tuesday, Oct. 29.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41429862/this-analyst-with-85-accuracy-rate-sees-around-11-upside-in-netflix-here-are-5-stock-picks-for-last">This Analyst With 85% Accuracy Rate Sees Around 11% Upside In Netflix &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

ATNI

BOOM

IRTC

KSCP

MKTW

NTBL

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares increased by 241.4% to $1.41 during Monday's regular session. The company's market cap stands at $3.6 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 224.11% to $0.8. The market value of their outstanding shares is at $5.9 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 111.91% to $4.98. The market value of their outstanding shares is at $39.7 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares moved upwards by 91.17% to $1.11. The company's market cap stands at $3.2 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares increased by 43.07% to $0.28. The company's market cap stands at $3.8 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares moved upwards by 38.8% to $6.76. The market value of their outstanding shares is at $224.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares fell 28.5% to $3.62 during Monday's regular session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock decreased by 19.17% to $0.85. The market value of their outstanding shares is at $21.6 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock declined by 18.65% to $0.04. The market value of their outstanding shares is at $4.5 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares fell 15.24% to $5.34. The market value of their outstanding shares is at $224.2 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares fell 14.53% to $14.1. The company's market cap stands at $2.2 billion. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock declined by 11.6% to $1.22. The company's market cap stands at $1.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GRTS

MHUA

MOLN

NMRA

WORX

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mostly lower this morning, with the Dow Jones index falling over 50 points on Monday.
Following the market opening Monday, the Dow traded down 0.13% to 43,219.80 while the NASDAQ slipped 0.01% to 18,487.82. The S&amp;P 500 also fell, dropping, 0.04% to 5,862.15.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Energy shares jumped by 0.6% on Monday.
In trading on Monday, real estate shares fell by 0.7%.
Top Headline
Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) announced that on October 11, it modified its card processing agreement to extend the deadline for its 2025 notes from October 21 to December 23 and the early maturity date from December 31 to March 3.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares shot up 148% to $1.04.</li>
<li>Shares of GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) got a boost, surging 142% to $1.4050.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) shares were also up, gaining 125% to $2.27 after the company announced its next-generation SD7 Ultra series 5G mission-critical push-to-talk cellular radio handsets will be available on T-Mobile&#8217;s 5G network.</li>
</ul>
Equities Trading DOWN
<ul>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares dropped 22% to $4.0750.</li>
<li>Shares of JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) were down 23% to $1.61.</li>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) was down, falling 20% to $0.0378.</li>
</ul>
Commodities In commodity news, oil traded up 1.6% to $70.32 while gold traded up 0.8% at $2,751.70.
Silver traded up 3.5% to $34.395 on Monday, while copper rose 0.7% to $4.4150.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX fell 0.7% and France's CAC 40 fell 0.7%. Spain's IBEX 35 Index fell 0.4%, while London's FTSE 100 fell 0.2%.
Producer prices in Germany fell 1.4% year-over-year in September compared to a 0.8% decline in the prior two months.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.07%, Hong Kong's Hang Seng Index dipped 1.57%, China's Shanghai Composite Index gaining 0.20% and India's BSE Sensex falling 0.09%.
The People&#8217;s Bank of China cut its one-year loan prime rate by 25bps to 3.1% at the October fixing.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41427706/wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yield">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

EFSH

JDZG

SAVE

SYTA

US Stocks Edge Lower; Dow Falls 50 Points

GRI Bio Shares Resume Trade

GRI Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Up 124.1%

GRI Bio Shares Resume Trade Following Circuit Breaker Halt

<h3>Gainers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares increased by 234.5% to $1.94 during Monday's pre-market session. The market value of their outstanding shares is at $5.6 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares rose 56.09% to $3.67. The company's market cap stands at $29.2 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 45.1% to $0.13. The company's market cap stands at $1.4 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares moved upwards by 35.36% to $2.22. The market value of their outstanding shares is at $34.1 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 25.05% to $6.09. The market value of their outstanding shares is at $202.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares increased by 23.72% to $1.13. The company's market cap stands at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock declined by 18.4% to $0.04 during Monday's pre-market session. The company's market cap stands at $4.5 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock decreased by 10.37% to $0.45. The market value of their outstanding shares is at $15.2 million. </li>
<li>LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) shares fell 10.05% to $6.36. The company's market cap stands at $2.4 billion. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 10.01% to $0.99. The company's market cap stands at $2.8 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares declined by 9.97% to $2.62. The market value of their outstanding shares is at $2.2 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) shares declined by 9.04% to $2.77. The company's market cap stands at $28.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

LFST

LGMK

MNDR

PHIO

WINT

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock increased by 234.5% to $1.94 during Monday's pre-market session. The market value of their outstanding shares is at $5.6 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares moved upwards by 56.09% to $3.67. The market value of their outstanding shares is at $29.2 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 45.1% to $0.13. The market value of their outstanding shares is at $1.4 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock moved upwards by 35.36% to $2.22. The market value of their outstanding shares is at $34.1 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 25.05% to $6.09. The market value of their outstanding shares is at $202.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 23.72% to $1.13. The market value of their outstanding shares is at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock decreased by 18.4% to $0.04 during Monday's pre-market session. The company's market cap stands at $4.5 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares decreased by 10.37% to $0.45. The company's market cap stands at $15.2 million. </li>
<li>LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) stock fell 10.05% to $6.36. The market value of their outstanding shares is at $2.4 billion. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares fell 10.01% to $0.99. The market value of their outstanding shares is at $2.8 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares decreased by 9.97% to $2.62. The market value of their outstanding shares is at $2.2 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) stock fell 9.04% to $2.77. The market value of their outstanding shares is at $28.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) rose sharply in today's pre-market trading.
Spirit Airlines announced that on October 11, it modified its card processing agreement to extend the deadline for its 2025 notes from October 21 to December 23 and the early maturity date from December 31 to March 3.
Spirit Airlines shares jumped 43.5% to $2.11 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) rose 151.2% to $1.46 in pre-market trading after jumping around 19% on Friday. GRI Bio, last week, announced it presented preclinical data highlighting GRI-0621&#8217;s ability to inhibit invariant natural killer T cell activity.</li>
<li>BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) gained 98.7% to $4.67 in pre-market trading after jumping around 110% on Friday.</li>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares surged 60% to $4.48 in pre-market trading after declining 8% on Friday.</li>
<li>Genprex, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) rose 42.7% to $0.5980 in pre-market trading after gaining around 21% on Friday. Genprex recently announced it has advanced to the highest dose group in its Acclaim-3 trial for Reqorsa Gene Therapy with Tecentriq after receiving a safety review committee approval.</li>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares jumped 37.2% to $2.25 in pre-market trading after gaining around 18% on Friday.</li>
<li>Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares rose 16.6% to $0.2317 in pre-market trading after jumping around 24% on Friday.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) gained 16.1% to $0.4640 in pre-market trading after dipping 43% on Friday.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) climbed 15.2% to $5.82 in pre-market trading.</li>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) gained 15.2% to $0.1001 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares dipped 24.7% to $3.96 in pre-market trading after jumping around 199% on Friday.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares fell 21.5% to $1.64 in pre-market trading after jumping 23% on Friday.</li>
<li>Agrify Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) fell 12.7% to $3.61 in today's pre-market trading after jumping over 25% on Friday.</li>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) fell 11.3% to $0.6651 in pre-market trading after dipping 19% on Friday.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) shares declined 11.1% to $2.09 in pre-market trading after gaining over 4% on Friday.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares fell 8.7% to $3.78 in pre-market trading after jumping over 20% on Friday.</li>
<li>Qilian International Holding Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) shares declined 8.7% to $7.00 in pre-market trading.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) fell 8% to $0.0865 in pre-market trading after declining around 10% on Friday.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) declined 7.2% to $2.70 in pre-market trading after jumping 10% on Friday.</li>
<li>Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>) shares fell 5.6% to $0.8580 after jumping 106% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>

AGFY

MTEM

NKGN

SHLS

TNON

VSME

VTAK

XPON

ZPTA

Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock rose 66.5% to $2.73 during Friday's after-market session. The company's market cap stands at $41.9 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock moved upwards by 21.58% to $0.71. The company's market cap stands at $2.0 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares moved upwards by 5.67% to $1.49. The market value of their outstanding shares is at $20.1 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 5.49% to $0.44. The company's market cap stands at $10.4 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 5.14% to $0.09. The market value of their outstanding shares is at $4.6 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares moved upwards by 5.0% to $0.9. The market value of their outstanding shares is at $91.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares fell 7.8% to $2.86 during Friday's after-market session. The market value of their outstanding shares is at $26.3 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock decreased by 7.21% to $0.44. The market value of their outstanding shares is at $2.4 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock fell 7.03% to $0.79. The market value of their outstanding shares is at $3.1 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares declined by 6.45% to $0.47. The market value of their outstanding shares is at $14.0 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares fell 6.2% to $0.7. The company's market cap stands at $4.6 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock decreased by 5.81% to $2.11. The market value of their outstanding shares is at $62.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

CERO

HCTI

IMRX

KZIA

QNRX

SABS

TLSA

12 Health Care Stocks Moving In Friday's After-Market Session

WIIM

GRI Bio shares are trading higher after the company announced it presented preclinical data highlighting GRI-0621's ability to inhibit invariant natural killer T cell activity.

Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis &nbsp;
Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q4 2024 and topline data in Q1 2025
Data presented at the 22nd International Colloquium on Lung and Air

GRI Bio Presents Preclinical Data Highlighting GRI-0621's Ability To Inhibit Invariant Natural Killer T Cell Activity

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 123.5% to $0.85 during Monday's pre-market session. The market value of their outstanding shares is at $144.7 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares increased by 67.19% to $3.16. The market value of their outstanding shares is at $165.4 million. </li>
<li>Longboard Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) stock rose 51.28% to $58.85. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares rose 18.18% to $2.6. The company's market cap stands at $14.8 million. </li>
<li>Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) stock increased by 15.05% to $17.27. The market value of their outstanding shares is at $260.8 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares rose 13.86% to $2.3. The market value of their outstanding shares is at $67.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares declined by 78.5% to $0.32 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 16.77% to $0.82. The market value of their outstanding shares is at $8.2 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares declined by 11.9% to $3.63. The company's market cap stands at $4.8 million. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) shares declined by 8.87% to $26.0. The market value of their outstanding shares is at $790.6 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock decreased by 7.74% to $0.37. The market value of their outstanding shares is at $1.0 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined by 7.65% to $0.43. The market value of their outstanding shares is at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DWTX

HSTM

IMRN

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

LBPH

NIVF

RANI

VRPX

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are not for everyone, let&rsquo;s make that perfectly clear. It&rsquo;s challenging to invest in a field in which companies &ndash; particularly startups &ndash; can go for years without seeing a penny of revenue. 



While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get in too much trouble.



Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and technologies, working in the fields of gene therapy, personalized medicine and biologics.



The challenge in this sector is that it takes a long time to bring a new drug or therapy to market. 



Even after the drug or therapy is discovered and developed in a laboratory setting, biotech companies must undergo preclinical research and a series of clinical trials. All these trials must be successful to go to the next step in the process. 



Clinical trials can often be expensive and time-consuming. And if the drug or therapy passes all of that, it still needs to get approval from the Food and Drug Administration (and regulators in other countries) before it can be brought to market.



Well-established biotech companies that have a history of success can better withstand these issues if they&rsquo;ve previously brought drugs to market and are bringing in revenue. 



But for a new company that doesn&rsquo;t have a revenue stream, clinical trials can try the patience of any investor &ndash; particularly as a company goes deeper into debt.



The biotech stocks we&rsquo;re looking at today all have good ideas, but the hurdles they have to clear to turn the corner are extremely high. 



If you&rsquo;re going to invest in the biotech sector, you should consider avoiding these names &ndash; and if you&rsquo;re an investor, you should take this opportunity to recognize biotech stocks to sell now.



<h2>Ginkgo Bioworks (DNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/dna_ginkobioworks1600-300x169.png" alt="Person holding mobile phone with logo of American biotechnology company Ginkgo Bioworks Inc. on screen in front of web page. Focus on phone display. Unmodified photo. DNA stock"><div>Source: T. Schneider / Shutterstock.com</div></div>Ginkgo Bioworks (NYSE:<a href="https://investorplace.com/stock-quotes/dna-stock-quote/">DNA</a>) is a Boston-based company that uses genetic engineering to produce bacteria with industrial applications for other biotech companies.



The company specializes in cell programming and biosecurity. It&rsquo;s <a href="https://finance.yahoo.com/news/ginkgo-bioworks-novo-nordisk-expand-110200616.html">working</a> with Dutch biotech company Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) on several research and development projects over the next five years, including diabetes and obesity medications.



Ginkgo also <a href="https://www.syngenta.com/en/company/media/syngenta-news/year/2024/syngenta-collaborates-ginkgo-bioworks-enable-faster-launch">announced</a> a collaboration with agricultural company Syngenta to develop and optimize a microbial strain for a secondary metabolite in Syngenta&rsquo;s pipeline.



As promising as these sound, the reality doesn&rsquo;t match up. DNA stock is down 82% this year and the company has just been trying to maintain its New York Stock Exchange <a href="http://investors.ginkgobioworks.com/news/news-details/2024/Ginkgo-Bioworks-Receives-Continued-Listing-Standard-Notice-From-NYSE/default.aspx">listing compliance</a>.



The company also instituted deep staff cuts, <a href="https://investorplace.com/2024/06/ginkgo-bioworks-layoffs-expand-to-400-job-cuts/">laying off</a> at least 35% of its 1,200-member workforce. &nbsp;



Revenue in the first quarter was $38 million, down from $81 million in the first quarter of 2023. Overall, the company reported a loss of $178 million for the quarter.



DNA stock gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Tonix Pharmaceuticals (TNXP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/txnp-stock-quote/">TXNP</a>) is making drugs and therapies to treat central nervous system disorders. But like many other biotech companies, it&rsquo;s paying the bills is a challenge.



Tonix hasn&rsquo;t yet brought a drug to market. It does have a candidate in Phase 3 testing as a treatment for fibromyalgia. The company is hoping for FDA approval for its drug, Tonmya, in the second half 2025.



Tonix also has a therapy in Phase 2 trials that would treat long Covid-19 symptoms, but Tonmya is much closer to becoming a reality.



That&rsquo;s why the company&rsquo;s trying to raise money. It had&nbsp;<a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1490/tonix-pharmaceuticals-announces-closing-of-4-0-million">two separate $4 million public offerings in June</a>&nbsp;that will help, but also served to dilute investor equity. It also completed a 1-for-32 reverse stock split to regain Nasdaq listing compliance.



Tonix recorded a <a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1469/tonix-pharmaceuticals-reports-first-quarter-2024-financial">net loss of $14.9 million in the first quarter,</a>&nbsp;or 18 cents per share. It only had $7 million in cash on hand at the end of the quarter, so it needs all the money it can get from its fundraising efforts.



TNXP stock is already back below $1 per share, having dropped 93% in 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



Tonix stock is down 95% this year, getting an &ldquo;F&rsquo; rating in the Portfolio Grader.



<h2>Gain Therapeutics (GANX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div>Gain Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ganx-stock-quote/">GANX</a>) is a Maryland company that is developing possible therapies for neurodegenerative diseases, genetic disorders and cancer. 



The company lead candidate, which is in Phase 1 trials, has the potential to treat Parkinson&rsquo;s disease and other neurodegenerative diseases such as Gaucher disease, and Alzheimer&rsquo;s disease.



Gain also has a drug discovery platform called Magellan that uses artificial intelligence to help it develop therapies.



It&rsquo;s also trying to raise money, although doing so isn&rsquo;t a good deal for current shareholders. 



<a href="https://investorplace.com/2024/06/why-is-gain-therapeutics-ganx-stock-down-25-today/">Last month</a> it sold 7.11 million shares at $1.35 each in an effort to raise $11 million so it can continue testing its lead drug candidate. But the public offering also increased the number of shares in the company, which diluted shares.



It&rsquo;s also notable that CEO Matthias Alder abruptly left Gain in late June. He was replaced on an interim basis by Gene Mack, the chief financial officer.



All in all, Gain appears not to be on firm footing and is a long way from seeing revenue from its top drug candidate. The stock is down 62% this year and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>GlycoMimetics (GLYC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) is another Maryland company. It&rsquo;s working on developing glycobiology-based therapies for cancer and inflammatory disease.



Glycobiology involves working with carbohydrates or sugar chains in an effort to develop appropriate therapies.



But the company took a major hit this spring when Phase 3 trials of its lead drug candidate failed to be statistically significant. The drug, uproleselan, was bring developed for the treatment of relapsed/refractory acute myeloid leukemia.



The company <a href="https://www.nasdaq.com/press-release/glycomimetics-announces-results-of-pivotal-phase-3-study-of-uproleselan-in-relapsed">noted</a> that the study didn&rsquo;t &ldquo;achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.&rdquo; 



Patient survival reached a median of 13 months as compared to 12.3 months just with chemotherapy.



The company said it&rsquo;s planning to meet with regulators and the National Cancer Institute to determine a path forward. Meanwhile, the floor has fallen out from GLYC stock, which is down 87% on the year. It gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>GRI Bio (GRI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) is developing therapies to treat inflammatory disease. 



Its&nbsp;therapies would target the activity of Natural Killer T (&ldquo;NKT&rdquo;) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression.



The company has four drug candidates in its pipeline, with the most advanced being a treatment for idiopathic pulmonary fibrosis. That candidate is in Phase 2 trials.



Like many other early-stage biotech companies, GRI Bio is trying to raise money to keep the doors open, while at the same time <a href="https://gribio.com/gri-bio-regains-compliance-with-nasdaq/">trying not to be delisted by the index</a>.



The company announced late last month that it would sell more than 2 million shares of GRI stock &ndash; an <a href="https://investorplace.com/2024/06/why-is-gri-bio-gri-stock-down-29-today/">announcement</a> that sent the stock price down by 29%.



GRI stock is now down 95% in 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Ovid Therapeutics (OVID)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Ovid Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ovid-stock-quote/">OVID</a>) is a biotech company that is working to create therapies to combat neurological diseases. 



Its drug candidate to treat brainstem malformations completed Phase 1 trials, while three other drug candidates are not as far advanced.



Ovid also has a partnership with Takeda to bring another drug, soticlestat to market to treat Dravet syndrome and Lennox-Gastaut syndrome. 



Both therapies are in Phase 3 trials, but the top-line study results are not promising. 



The treatment for Dravet syndrome narrowly missed its primary endpoint in reducing the frequency of seizures, and its treatment for Lennox-Gastaut syndrome missed its mark in reducing motor drop seizures.



Ovid only had revenue of <a href="https://investors.ovidrx.com/news/news-details/2024/Ovid-Therapeutics-Reports-Business-Updates-and-First-Quarter-2024-Financial-Results/default.aspx">$148,000 in the first quarter</a> versus operating expenses of $17.2 million. The company has roughly $90 million of cash on hand, so it&rsquo;s not at immediate risk. But it&rsquo;s also a long way from turning a profit as well.



OVID stock is down 70% this year &ndash; with much of that drop coming after the Phase 3 trials on soticlestat were released. and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>Cosmos Health (<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Cosmos Health (NASDASQ:<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>) is a Chicago company that serves as a holding company. 



Its portfolio includes pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept.



The company also operates a subsidiary, Cana Laboratories, to manufacture pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. 



The company makes and sells branded generics and over-the-counter medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the U.K.



The company has not yet filed its fourth-quarter report, and received a notice of noncompliance from Nasdaq for the failure. 



But its third-quarter report included a couple of red flags, including a drop in year-to-date revenue from $38.3 million to $37.5 million; and a drop in cash from $20.7 million to $2.3 million.



COSM stock is down 10% this year and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier had a long position in NVO. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/07/7-sorry-biotech-stocks-set-to-make-investors-sad-2/">7 Sorry Biotech Stocks Set to Make Investors Sad</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Sorry Biotech Stocks Set to Make Investors Sad

GRI Bio (GRI) has provided an announcement. The provided information, including any exhibits, is for informational purposes only and should not be ...

GRI Bio Shares Informational Update Not for Legal Use

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) just reported results for the second quarter of 2024.<ul><li>GRI Bio reported earnings per share of -$4.92.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/gri-stock-earnings-gri-bio-for-q2-of-2024/">GRI Stock Earnings: GRI Bio Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GRI Stock Earnings: GRI Bio Reported Results for Q2 2024

GRI Bio reports Q2 results

Warning: GRI is at high risk of performing badly

GRI Bio (GRI) announced that on October 22, 2024 it closed its previously announced transaction involving the exercise of certain existing warrants...

GRI Bio raises $13.9M in gross proceeds since start of 2024

COSM

GANX

GLYC

OVID

Press Releases

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio Participates in Virtual Investor KOL Connect Segment

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Top Innovation Stocks Surge: PRSO, SYTA, SAVE, ISPC, GRI, BIVI – Must-Watch Stocks This Week

GRI Bio Announces Exercise of Warrants

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Comments

GRI Bio

Notizie

Ultime notizie per GRI Bio (NASDAQ:GRI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO